Every 10-Q that Aspire-Lakewood Holdings, Inc. (ASBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASBP filings page.
Aspire Biopharma Holdings, Inc. reported minimal commercial activity but a much stronger balance sheet for the quarter and six months ended June 30, 2026. Net revenue was $63,104 for the quarter and $91,457 for the first half of 2026, producing a negative gross margin due to $73,421 of cost of revenue and a $42,372 inventory write-off. The company remains in an early commercialization phase.
The operating loss was $2.68 million for the quarter and $4.32 million year-to-date, but total net loss of $4.49 million for the first half of 2026 improved significantly from $17.92 million a year earlier as prior-period stock-based compensation and financing-related charges rolled off. Cash and cash equivalents increased to $12.17 million from $1.00 million at December 31, 2025, and working capital reached $11.78 million.
Major capital structure changes included issuance of 26,250 shares of Series A Convertible Preferred Stock in February and April 2026, of which 17,050 remained outstanding at June 30, 2026, and multiple conversions of debt and preferred stock into common shares, increasing common shares outstanding to 1,295,234 after two reverse stock splits. Total liabilities fell to $1.78 million from $7.69 million, turning a $(6.38) million stockholders’ deficit into positive equity of $11.76 million. Management states existing liquidity is sufficient to fund operations for at least one year after issuance of these statements.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company focused on sublingual delivery of known drugs and supplements, reported its unaudited results for the quarter ended March 31, 2026.
The company generated its first reported commercial revenue, with net revenue of $28,353 from nutraceutical products, producing a modest gross margin of $5,750. Operating expenses were driven mainly by general and administrative costs of $1,020,457, research and development of $296,723, and sales and marketing of $334,739, leading to a loss from operations of $1,646,169. Including other expense, primarily related to financing activities, Aspire recorded a net loss of $3,222,892, a substantial improvement from the prior year period’s loss of $15,941,328, which had been inflated by large stock-based compensation.
The balance sheet strengthened significantly. Cash and cash equivalents rose to $5,857,024 from $1,003,904 at year-end, and total assets increased to $7,117,147. Total liabilities declined to $3,248,684 from $7,688,495, reflecting repayment and conversion of prior debt. Stockholders moved from a deficit of $(6,376,329) to positive equity of $3,868,463, aided by issuances of Series A convertible preferred stock and common shares issued for debt exchanges and financing fees.
Operating cash outflows were $3,038,522, but Aspire received $7,891,642 in net cash from financing activities, including Series A preferred proceeds and debentures. Management disclosed that available liquidity, including cash from a February and April 2026 preferred stock financing and an equity line of credit allowing up to $100 million in common stock sales over 24 months, is expected to fund operations for at least one year after the financial statements’ filing date.
Aspire Biopharma Holdings, Inc. filed an amended quarterly report (10‑Q/A) for the quarter ended September 30, 2025 to correct a typographical error in MD&A “Nasdaq Notices.” The report is refiled in full; no other changes were made.
For the quarter, the company reported net revenue of $1,941 and a net loss of $1,850,493; the nine‑month net loss was $19,773,114. Cash was $1,948,271 with a working capital deficit of $11,457,377 as of September 30, 2025. Current liabilities totaled $13,860,506, including a derivative liability of $3,554,265 and a convertible note balance of $4,739,965. Management disclosed that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern. As of November 12, 2025, there were 107,477,178 shares of common stock outstanding and 24,138,302 warrants outstanding.
Aspire Biopharma Holdings, Inc. (ASBP) filed its Q3 2025 report following a February reverse acquisition. The company generated minimal net revenue of $1,941 and reported a net loss of $1,850,493 for the quarter, bringing the nine‑month net loss to $19,773,114. Operating expenses were driven largely by general and administrative costs and research and development.
Liquidity remains tight. Cash was $1,948,271 with a working capital deficit of $11,457,377, and management disclosed substantial doubt about the company’s ability to continue as a going concern. The balance sheet shows a shareholders’ deficit of $(11,467,278), current liabilities of $13,860,506, and a derivative liability of $3,554,265. Convertible notes included a current balance of $4,739,965, alongside a subscription agreement loan of $1,500,000 and a related‑party promissory fee of $1,000,000.
The company closed new financing in August and September via notes totaling $9,687,500 in principal (funded $7,750,000 before costs), recorded a derivative liability, and repaid portions of earlier debentures. Shares outstanding were 49,525,970 as of September 30, 2025; 107,477,178 shares and 24,138,302 warrants were outstanding as of November 12, 2025.